{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:02:40Z","timestamp":1792454560849,"version":"4.5.0"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Natl J Maxillofac Surg"],"published-print":{"date-parts":[[2022]]},"DOI":"10.4103\/njms.njms_236_20","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T02:48:30Z","timestamp":1645152510000},"page":"5","source":"Crossref","is-referenced-by-count":41,"title":["Medication-related osteonecrosis of the jaw: An update"],"prefix":"10.4103","volume":"13","author":[{"given":"Hitesh","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0975-5950.337885-1","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1007\/s00586-003-0622-z","article-title":"Bisphosphonates in osteoporosis","author":"Fleisch","year":"2003","journal-title":"Eur Spine J"},{"key":"key-10.4103\/0975-5950.337885-2","first-page":"27","article-title":"Bisphosphonates in oncology: Evidence for the prevention of skeletal events in patients with bone metastases","author":"Polascik","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"key-10.4103\/0975-5950.337885-3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1634\/theoncologist.2010-0225","article-title":"The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future","author":"Pozzi","year":"2011","journal-title":"Oncologist"},{"key":"key-10.4103\/0975-5950.337885-4","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/0975-5950.337885-5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0975-5950.337885-6","unstructured":"Joint Formulary Committee. British National Formulary (Online) London: BMJ Group and Pharmaceutical Press. Zoledronic Acid. Available from: https:\/\/www.medicinescomplete.com\/#\/content\/bnf\/_664056927?hspl=Zoledronic%20acid. [Last acessed on 2020 Sep 14]."},{"key":"key-10.4103\/0975-5950.337885-7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-9","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphanates and oral cavity avascular bone necrosis","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0975-5950.337885-10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0975-5950.337885-11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"key-10.4103\/0975-5950.337885-12","unstructured":"Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Denosumab. Available from: https:\/\/www.medicinescomplete.com\/#\/content\/bnf\/_442118148?hspl=Denosumab. [Last accessed on 2020 Sep 14]."},{"key":"key-10.4103\/0975-5950.337885-13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on Denosumab","author":"Aghaloo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-15","first-page":"13","article-title":"The aging population: Demographics and the biology of aging","author":"Kanasi","year":"2000","journal-title":"Periodontol"},{"key":"key-10.4103\/0975-5950.337885-16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijc.33232","article-title":"Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050","author":"Pilleron","year":"2021","journal-title":"Int J Cancer"},{"key":"key-10.4103\/0975-5950.337885-17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bone.2005.11.024","article-title":"Osteoporosis: A still increasing prevalence","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"key-10.4103\/0975-5950.337885-18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0975-5950.127643","article-title":"Bisphophonates related osteonecrosis of the jaw","author":"Gupta","year":"2013","journal-title":"Natl J Maxillofac Surg","ISSN":"https:\/\/id.crossref.org\/issn\/0975-5950","issn-type":"print"},{"key":"key-10.4103\/0975-5950.337885-19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.joms.2009.05.293","article-title":"Diagnosis of BRONJ","author":"Ruggiero,","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjoms.2014.09.001","article-title":"Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed","author":"Fedele","year":"2015","journal-title":"Br J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"key-10.4103\/0975-5950.337885-22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"key-10.4103\/0975-5950.337885-24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: Different mechanisms of action and effects","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"key-10.4103\/0975-5950.337885-25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","author":"Aghaloo","year":"2011","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/0975-5950.337885-26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ar.a.20396","article-title":"Remodeling dynamics in the alveolar process in skeletally mature dogs","author":"Huja","year":"2006","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"key-10.4103\/0975-5950.337885-27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1359\/jbmr.080516","article-title":"Review of nonprimate, large animal models for osteoporosis research","author":"Reinwald","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/0975-5950.337885-28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00428-007-0516-2","article-title":"Actinomycosis of the jaws - histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis","author":"Hansen","year":"2007","journal-title":"Virchows Arch"},{"key":"key-10.4103\/0975-5950.337885-29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.joms.2007.11.035","article-title":"Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy","author":"Sedghizadeh","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/10454411990100020101","article-title":"Molecular and genetic analyses of Actinomyces spp","author":"Yeung","year":"1999","journal-title":"Crit Rev Oral Biol Med"},{"key":"key-10.4103\/0975-5950.337885-31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol"},{"key":"key-10.4103\/0975-5950.337885-32","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/jbmr.1894","article-title":"Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice","author":"Kang","year":"2013","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/0975-5950.337885-33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"key-10.4103\/0975-5950.337885-34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1749-6632.2010.05835.x","article-title":"Potential pathophysiological mechanisms in osteonecrosis of the jaw","author":"Landesberg","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/0975-5950.337885-35","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0975-5950.337885-36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"key-10.4103\/0975-5950.337885-37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/0975-5950.337885-38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","article-title":"Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people","author":"Cartsos","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"key-10.4103\/0975-5950.337885-39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/0975-5950.337885-40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-41","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3899\/jrheum.100221","article-title":"Bisphosphonate-associated osteonecrosis of the jaw in Ontario: A survey of oral and maxillofacial surgeons","author":"Khan","year":"2011","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0975-5950.337885-42","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/pds.3292","article-title":"Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis","author":"Tennis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.4103\/0975-5950.337885-43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.11005\/jbm.2015.22.4.151","article-title":"Medication related osteonecrosis of the jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons","author":"Kim","year":"2015","journal-title":"J Bone Metab"},{"key":"key-10.4103\/0975-5950.337885-44","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","article-title":"Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate","author":"Walter","year":"2008","journal-title":"Eur Urol"},{"key":"key-10.4103\/0975-5950.337885-45","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: A cohort study","author":"Yamazaki","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"key-10.4103\/0975-5950.337885-47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key-10.4103\/0975-5950.337885-48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/ccd.ccd_696_17","article-title":"Osteonecrosis of the jaw among patients receiving antiresorptive medication: A 4-year retrospective study at a tertiary cancer center, Kerala, India","author":"Sankar","year":"2018","journal-title":"Contemp Clin Dent","ISSN":"https:\/\/id.crossref.org\/issn\/0976-237X","issn-type":"print"},{"key":"key-10.4103\/0975-5950.337885-49","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0975-5950.337885-50","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0975-5950.337885-51","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients","author":"Kyrgidis","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0975-5950.337885-52","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-53","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","article-title":"Possible association between diabetes and bisphosphonate-related jaw osteonecrosis","author":"Khamaisi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/0975-5950.337885-54","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management","author":"Ruggiero","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"key-10.4103\/0975-5950.337885-55","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series","author":"Fedele","year":"2010","journal-title":"Am J Med"},{"key":"key-10.4103\/0975-5950.337885-56","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.joms.2009.03.005","article-title":"Intravenous bisphosphonate-related osteonecrosis of the jaw: Bone scintigraphy as an early indicator","author":"O'Ryan","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0975-5950.337885-58","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience","author":"Vandone","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0975-5950.337885-59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bjoms.2010.05.007","article-title":"Bisphosphonate osteonecrosis of the jaw \u2013 A literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention","author":"Patel","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates.The experience of the National Cancer Institute of Milan","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0975-5950.337885-61","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"key-10.4103\/0975-5950.337885-62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.oraloncology.2013.06.008","article-title":"Osteonecrosis of the jaw - Prevention and treatment strategies for oral health professionals","author":"Hinchy","year":"2013","journal-title":"Oral Oncol"},{"key":"key-10.4103\/0975-5950.337885-63","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"key-10.4103\/0975-5950.337885-64","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","author":"Khan","year":"2008","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0975-5950.337885-65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bjoms.2011.08.004","article-title":"Treatment of bisphosphonate-related osteonecrosis of the jaws: Presentation of a protocol and an observational longitudinal study of an Italian series of cases","author":"Ferlito","year":"2012","journal-title":"Br J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-66","first-page":"331","article-title":"Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome","author":"Van","year":"2009","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0975-5950.337885-67","first-page":"4209","article-title":"Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review","author":"de","year":"2019","journal-title":"Head Neck"},{"key":"key-10.4103\/0975-5950.337885-68","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","author":"Bashutski","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0975-5950.337885-69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","article-title":"The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw","author":"Wilde","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"key-10.4103\/0975-5950.337885-70","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: A systematic review","author":"Fliefel","year":"2015","journal-title":"Int J Oral Maxillofac Surg"},{"key":"key-10.4103\/0975-5950.337885-71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bjoms.2010.08.005","article-title":"Bisphosphonate osteonecrosis of the jaw: A literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw","author":"McLeod","year":"2011","journal-title":"Br J Oral Maxillofac Surg"}],"container-title":["National Journal of Maxillofacial Surgery"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:30:00Z","timestamp":1787164200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njms.NJMS_236_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["337885"],"URL":"https:\/\/doi.org\/10.4103\/njms.njms_236_20","relation":{},"ISSN":["0975-5950"],"issn-type":[{"value":"0975-5950","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}